Wall Street analysts predict that Sierra Oncology, Inc. (NASDAQ:SRRA) will announce earnings per share of ($1.61) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Sierra Oncology’s earnings. The highest EPS estimate is ($1.45) and the lowest is ($1.76). Sierra Oncology posted earnings per share of ($1.31) in the same quarter last year, which indicates a negative year over year growth rate of 22.9%. The firm is expected to report its next earnings results on Thursday, May 6th.
On average, analysts expect that Sierra Oncology will report full year earnings of ($6.28) per share for the current financial year, with EPS estimates ranging from ($7.50) to ($5.18). For the next fiscal year, analysts expect that the firm will post earnings of ($4.89) per share, with EPS estimates ranging from ($5.03) to ($4.74). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last issued its quarterly earnings data on Thursday, March 11th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.11).
Sierra Oncology stock traded down $0.56 during midday trading on Tuesday, hitting $17.58. The company’s stock had a trading volume of 10,207 shares, compared to its average volume of 40,040. Sierra Oncology has a 1-year low of $9.32 and a 1-year high of $20.43. The company has a 50-day moving average price of $16.49 and a two-hundred day moving average price of $14.80. The company has a market cap of $204.42 million, a price-to-earnings ratio of -1.26 and a beta of 1.31.
A number of hedge funds have recently added to or reduced their stakes in SRRA. Ghost Tree Capital LLC bought a new position in Sierra Oncology in the 4th quarter valued at about $3,206,000. Silverarc Capital Management LLC bought a new position in Sierra Oncology in the 4th quarter valued at about $2,164,000. Opaleye Management Inc. bought a new position in Sierra Oncology in the 4th quarter valued at about $1,208,000. Boothbay Fund Management LLC bought a new position in Sierra Oncology in the 3rd quarter valued at about $405,000. Finally, Morgan Stanley grew its holdings in shares of Sierra Oncology by 2,626.1% during the 3rd quarter. Morgan Stanley now owns 10,250 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 9,874 shares during the last quarter. 62.32% of the stock is currently owned by hedge funds and other institutional investors.
Sierra Oncology Company Profile
Sierra Oncology, Inc researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis.
Further Reading: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.